Small study but clinical. I don't even know if it could be called phase 1, but at least on humans.
The study, published in Cell Reports Medicine, focuses on a new treatment combining pembrolizumab with standard chemotherapy to treat small cell bladder cancer and small cell/neuroendocrine prostate cancer. Small cell carcinomas are aggressive and have a low survival rate. This new combination therapy resulted in 43% of patients experiencing disease regression and showed increased survival rates. The study was conducted on 15 patients, and further research is needed to confirm the findings. The combination treatment was well-tolerated with no reported side effects.
